SEARCH

SEARCH BY CITATION

References

  • Akwa Y., Purdy R. H., Koob G. F. and Britton K. T. (1999) The amigdala mediates the anxiolitic-like effect of neurosteroid allopregnanolone in rat. Behav. Brain Res. 106, 119125.
  • Aoki C. and Pickel V. M. (1990) Neuropeptide Y in cortex and striatum. Ultrastructural distribution and coexistence with classical neurotransmitters and neuropeptides. Ann. NY Acad. Sci. 611, 186205.
  • Azzolina B., Ellsworth K., Andersson S., Geissler W., Bull. H. G. and Harris G. S. (1997) Inhibition of rat α-reductases by finasteride: evidence for isozyme differences in the mechanism of inhibition. J.Steroid Biochem. Mol. Biol. 61, 5564.
  • Bannon A. W., Seda J., Carmouche M., Francis J. M., Norman M. H., Karbon B. and McCaleb M. L. (2000) Behavioral characterization of neuropeptide Y knockout mice. Brain Res. 868, 7987.
  • Belelli D., Bolger M. B. and Gee K. W. (1989) Anticonvulsant profile of the progesterone metabolite 5α-pregnan-3α-ol-20-one. Eur. J.Pharmacol. 166, 325329.
  • Biggio G. and Purdy R. H., eds. (2001) International Review of Neurobiology, Vol. 46: Neurosteroids and Brain Function. Academic Press, San Diego.
  • Biggio G., Follesa P., Sanna E., Purdy R. H. and Concas A. (2001) GABAA-receptor plasticity during long-term exposure to and withdrawal from progesterone. Int. Rev. Neurobiol. 46, 207241.
  • Bitran D., Hilvers R. J. and Kellogg C. K. (1991) Anxiolytic effects of 3α-hydroxy-5α[β]-pregnan-20-one: endogenous metabolites of progesterone that are active at the GABAA receptor. Brain Res. 561, 157161.
  • Britton K. T., Southerland S., Van Uden E., Kirby D., Rivier J. and Koob G. (1997) Anxiolytic activity of NPY receptor agonists in the conflict test. Psychopharmacology 132, 613.DOI: 10.1007/s002130050313
  • Britton K. T., Akwa Y., Spina M. G. and Koob G. F. (2000) Neuropeptide Y blocks anxiogenic-like behavioral action of corticotropin-releasing factor in an operant conflict test and elevated plus maze. Peptides 21, 3744.
  • Broqua P., Wettstein J. G., Rocher M. N., Gauthier-Martin B. and Junien J. L. (1995) Behavioral effects of neuropeptide Y receptor agonists in the elevated plus-maze and fear-potentiated startle procedures. Behav. Pharmacol. 6, 215222.
  • Brot M. D., Akwa Y., Purdy R. H., Koob G. F. and Britton K. T. (1997)The anxiolytic-like effects of the neurosteroid allopregnanolone: interactions with GABAA receptors. Eur. J. Pharmacol. 325, 17.
  • Concas A., Mostallino M. C., Perra C., Lener R., Roscetti G., Barbaccia M. L., Purdy R. H. and Biggio G. (1996) Functional correlation between allopregnanolone and [35S]-TBPS binding in the brainofrats exposed to isoniazid, pentylenetetrazol or stress. Br.J.Pharmacol. 118, 839846.
  • Concas A., Mostallino M. C., Porcu P., Follesa P., Barbaccia M. L., Trabucchi M., Purdy R. H., Grisenti P. and Biggio G. (1998) Role of brain allopregnanolone in the plasticity of gamma-aminobutyric acid type A receptor in rat brain during pregnancy and after delivery. Proc. Natl Acad. Sci. USA 95, 1328413289.
  • Concas A., Follesa P., Barbaccia M. L., Purdy R. H. and Biggio G. (1999) Physiological modulation of GABAA receptor plasticity by progesterone metabolites. Eur. J. Pharmacol. 375, 225235.
  • Davis M., Rainnie D. and Cassell M. (1994) Neurotransmission in the rat amygdala related to fear and anxiety. Trends Neurosci. 17, 208214.
  • Devaud L. L., Fritschy J. M., Sieghart W. and Morrow A. L. (1997) Bidirectional alterations of GABAA receptor subunit peptide levels in rat cortex during chronic ethanol consumption and withdrawal. J. Neurochem. 69, 126130.
  • Engel S. R. and Grant K. A. (2001) Neurosteroids and behavior. Int. Rev. Neurobiol. 46, 321348.
  • Erickson J., Clegg K. and Palmiter R. (1996) Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature 381, 415418.
  • Ferrara G., Serra M., Zammaretti F., Pisu M. G., Panzica G. C., Biggio G. and Eva C. (2001) Chronic treatment with progesterone and with allopregnanolone increases NPY-Y1 receptor gene expression in the medial amygdaloid nucleus of transgenic mice. J. Neurochem. 79, 417425.
  • Follesa P., Floris S., Tuligi G., Mostallino M. C., Concas A. and Biggio G. (1998) Molecular and functional adaptation of the GABAA receptor complex during pregnancy and after delivery in the rat brain. Eur. J. Neurosci. 10, 29052912.
  • Follesa P., Serra M., Cagetti E., Pisu M. G., Porta S., Floris S., Massa F., Sanna E. and Biggio G. (2000) Allopregnanolone synthesis in cerebellar granule cells: roles in regulation of GABAA receptor expression and function during progesterone treatment and withdrawal. Mol. Pharmacol. 57, 12621270.
  • Follesa P., Concas A., Porcu P., Sanna E., Serra M., Mostallino M. C., Purdy R. H. and Biggio G. (2001) Role of allopregnanolone inregulation of GABAA receptor plasticity during long-term exposure and withdrawal from progesterone. Brain Res. Rev. 37, 8190.
  • Franklin K. B. J. and Paxinos G. (1997) The Mouse Brain in Stereotaxic Coordinates. Academic Press, San Diego and New York.
  • Frye C. A. (1995) The neurosteroid 3α,5α-THP has antiseizure and possible neuroprotective effects in an animal model of epilepsy. Brain Res. 696, 113120.
  • Fuxe K., Agnati L., Harfstrand A., Zini I., Tatemoto K., Pich E., Hokfelt V., Mutt V. and Terenius L. (1983) Central administrationof neuropeptide Y induces hypotension bradypnea and EEGsynchronization in the rat. Acta Physiol. Scand. 118, 189192.
  • Griebel G. (1999) Is there a future for neuropeptide receptor ligands inthe treatment of anxiety disorders? Pharmacol. Ther. 82, 161.
  • Griffin L. D., Conrad S. C. and Mellon S. H. (2001) Current perspectives on the role of neurosteroids in PMS and depression. Int. Rev. Neurobiol. 46, 479492.
  • Gue M., Junien J. L., Reeve J. R. Jr, Rivier J., Grandt D. and Tache Y. (1996) Reversal by NPY, PYY and 3–36 molecular forms of NPY and PYY of intracisternal CRF-induced inhibition of gastric acid secretion in rats. Br. J. Pharmacol. 118, 237242.
  • Gustafson E. L., Card J. P. and Moore R. Y. (1986) Neuropeptide Y localization in the rat amygdaloid complex. J. Comp. Neurol. 251, 349362.
  • Heilig M. (1995) Antisense inhibition of neuropeptide Y (NPY)-Y1 receptor expression blocks the anxiolytic-like action of NPY in amygdala and paradoxically increases feeding. Reg. Peptides 41, 6169.
  • Heilig M., Soderpalm B., Engel J. and Widerlov E. (1989) Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models. Psychopharmacology 94, 524529.
  • Heilig M., McLeod S., Brot M., Heinrichs S. C., Menzaghi F., Koob G.F. and Britton K. T. (1993) Anxiolytic-like action of neuropeptide Y: mediation by Y1 receptors in amygdala, and dissociation from foodintake effects. Neuropsychopharmacology 8, 357363.
  • Heilig M., Koob G. F., Elkman R. and Britton K. T. (1994) Corticotropin-releasing factor and neuropeptide Y: role in emotional integration. Trends Neurosci. 17, 8085.
  • Heinrichs S. C., Menzaghi F., Pich E. M., Hauger R. L. and Koob G. F. (1993) Corticotropin-releasing factor in the paraventricular nucleus modulates feeding induced by neuropeptide Y. Brain Res. 611, 1824.
  • Hendry S. H. (1993) Organization of NPY neurons in the mammalian central nervous system, in The Biology of Neuropeptide Y and Related Peptides (ColmersW. F. and WahlestedtC., eds), pp. 65156, Humana, Totowa, NJ.
  • Hendry S. H., Jones E. G., DeFelipe J., Schmechel D., Brandon C. and Emson P. C. (1984) Neuropeptide-containing neurons of the cerebral cortex are also GABAergic. Proc. Natl Acad. Sci. USA 81, 65266530.
  • Horvath T. L., Bechmann I., Naftolin F., Kalra S. P. and Leranth C. (1997) Heterogeneity in the neuropeptide Y-containing neurons of the rat arcuate nucleus: GABAergic and non-GABAergic subpopulations. Brain Res. 756, 283286.
  • Kalra S. P., Dube M. G., Pu S., Xu B., Horvath T. L. and Kalra P. S. (1999) Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocrine Rev. 20, 68100.
  • Kask A., Rago L. and Harro J. (1996) Anxiogenic-like effect of the neuropeptide Y Y1 receptor antagonist BIBP3226: antagonism with diazepam. Eur. J. Pharmacol. 317, R3R4.
  • Kask A., Rago L. and Harro J. (1997) α-Helical CRF9-41 prevents anxiogenic-like effect of NPY Y1 receptor antagonist BIBP3226 in rats. Neuroreport 8, 36453647.
  • Kask A., Nguyen H. P., Pabst R. and Von Hörsten S. (2001) Neuropeptide Y Y1 receptor-mediated anxiolysis in the dorsocaudal lateral septum: functional antagonism of corticotropin-releasing hormone-induced anxiety. Neuroscience 104, 799806.DOI: 10.1016/S0306-4522(01)00116-6
  • Kokate T. G., Svensson B. E. and Rogawski M. A. (1994) Anticonvulsant activity of neurosteroids: correlation with γ-aminobutyric acid-evoked chloride current potentiation. J. Pharmacol. Exp. Ther. 270, 12231229.
  • Lambert J. J., Belelli D., Hill-Venning C. and Peters A. P. (1995) Neurosteroids and GABAA receptor function. Trends Pharmcol. Sci. 16, 295303.
  • LeDoux J. E. (2000) Emotion: circuits in the brain. Annu. Rev. Neurosci. 23, 155184.
  • Lowry O. H., Rosebrough N. J., Farr A. L. and Randall L. J. (1951) Protein measurement with the folin phenol reagent. J. Biol. Chem. 193, 265276.
  • Majewska M. D. (1992) Neurosteroids: endogenous bimodal modulators of the GABAA receptor. Mechanism of action and physiological significance. Prog. Neurobiol. 38, 379395.
  • Majewska M. D., Harrison N. L., Schwartz R. D., Barker J. L. and Paul S. M. (1986) Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science 232, 10041007.
  • McDonald A. J. and Pearson J. C. (1989) Coexistence of GABA and peptide immunoreactivity in non-pyramidal neurons of the basolateral amygdala. Neurosci. Lett. 100, 5358.
  • Naveilhan P., Canals J. M., Arenas E. and Ernfors P. (2001a) Distinct roles of the Y1 and Y2 receptors on neuropeptide Y-induced sensitization to sedation. J. Neurochem. 78, 12011207.DOI: 10.1046/j.1471-4159.2001.00534.x
  • Naveilhan P., Canals J. M., Valjakka A., Vartiainen J., Arenas E. and Ernfors P. (2001b) Neuropeptide Y alters sedation through a hypothalamic Y1-mediated mechanism. Eur. J. Neurosci. 13, 22412246.
  • Oberto A., Tolosano E., Brusa R., Altruda F., Panzica G. and Eva C. (1998) The murine Y1 receptor 5′ upstream sequence directs cell-specific and developmentally regulated LacZ expression in transgenic mice CNS. Eur. J. Neurosci. 10, 32573268.
  • Oberto A., Panzica G., Altruda F. and Eva C. (2000) Chronic modulation of GABAA receptor complex regulates Y1 receptor gene expression in the medial amygdala of transgenic mice. Neuropharmacology 39, 227234.DOI: 10.1016/S0028-3908(99)00129-X
  • Oberto A., Panzica G. C., Altruda F. and Eva C. (2001) GABAergic and NPY-Y1 network in the medial amygdala: a neuroanatomical basis for their functional interaction. Neuropharmacology 41, 639642.DOI: 10.1016/S0028-3908(01)00109-5
  • Ovesjö M. L., Gamstedt M., Collin M. and Meister B. (2001) GABAergic nature of hypothalamic leptin target neurones in the ventromedial arcuate nucleus. J. Neuroendocrinol. 13, 505516.
  • Paul S. M. and Purdy R. H. (1992) Neuroactive steroids. FASEB J. 6, 23112322.
  • Pu S., Jain M. R., Horvath T. L., Diano S., Kalra P. S. and Kalra S. P. (1999) Interactions between neuropeptide Y and γ-aminobutyric acid in stimulation of feeding: a morphological and pharmacological analysis. Endocrinology 140, 933940.
  • Puia G., Santi M. R., Vicini S., Pritchett D. B., Purdy R. H., Paul S. M., Seeburg P. H. and Costa E. (1990) Neurosteroids act on recombinant human GABAA receptors. Neuron 4, 759765.
  • Purdy R. H., Morrow A. L., Blinn J. R. and Paul S. M. (1990) Synthesis, metabolism and pharmacological activity of 3α-hydroxy-steroids which potentiate GABA-receptor-mediated chloride ion uptake in rat cerebral cortical synaptoneurosomes. J. Med. Chem. 33, 15721581.
  • Rupprecht R. and Holsboer F. (1999) Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci. 22, 410416.
  • Rupprecht E., Reul J. M. H. M., Trapp T., Van Steensel B., Wetzel C., Damm K., Zieglgänsberger W. and Holsboer F. (1993) progesterone receptor-mediated neuroactive steroids. Neuron 11, 523530.
  • Sajdyk T. J., Vandergriff M. G. and Gehlert D. R. (1999) Amygdalar neuropeptide Y Y1 receptors mediate the anxiolytic-like actions of neuropeptide Y in the social interaction test. Eur. J. Pharmacol. 368, 143147.
  • Serra M., Pisu M. G., Littera M., Papi G., Sanna E., Tuveri F., Usala L., Purdy R. H. and Biggio G. (2000) Social isolation-induced decreases in both the abundance of neuroactive steroids and GABAA receptor function in rat brain. J. Neurochem. 75, 732740.
  • Smith S. S., Gong Q. H., Hsu F. C., Markowitz R. S., Ffrench-Mullen J.M. and Li X. (1998a) GABAA receptor α4 subunit suppression prevents withdrawal properties of an endogenous steroid. Nature 392, 926930.
  • Smith S. S., Gong Q. H., Li X., Moran M. H., Bitran D., Frye C. A. and Hsu F. C. (1998b) Withdrawal from 3α-OH-5α-pregnan-20-one using a pseudopregnancy model alters the kinetics of hippocampal GABAA-gated current and increases the GABAA receptor α4 subunit in association with increased anxiety. J. Neurosci. 18, 52755284.
  • Tatemoto K., Carlquist M. and Mutt V. (1982) Neuropeptide Y − a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature 296, 659660.
  • Thorsell A., Michalkiewicz M., Dumont Y., Quirion R., Caberlotto L., Rimondini R., Mathe A. A. and Heilig M. (2000) Behavioral insensitivity to restraint stress, absent fear suppression of behavior and impaired spatial learning in transgenic rats with hippocampal neuropeptide Y overexpression. Proc. Natl Acad. Sci. USA 97, 1285212857.
  • Vezzani A., Sperk G. and Colmer W. F. (1999) Neuropeptide Y: emerging evidence for a functional role in seizure modulation. Trends Neurosci. 22, 2530.
  • Wahlestedt C., Pich E. M., Koob G. F., Yee F. and Heilig M. (1993) Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science 259, 528531.
  • Wang M., Bäckström T., Sundström I., Wahlström G., Olsson T., Zhu D., Johansson I.-M., Björn I. and Bixio M. (2001) Neuroactive steroids and central nervous system disorders. Int. Rev. Neurobiol. 46, 421459.
  • Wettstein J. G., Broqua P., Rocher M. N. and Junien J. L. (1994) Attenuation of fear-potentiated startle by neuropeptide Y1 receptor agonists. Neuropeptides 26, 116117.
  • Wieland S., Lan N. C., Mirasedeghi S. and Gee K. W. (1991) Anxiolytic activity of the progesterone metabolite 5α-pregnan-3α-ol-20-one. Brain Res. 565, 263268.
  • Wisden W. and Morris B. J. (2002) In situ hybridization with oligonucleotide probes, in In situ Hybridization Protocols for the Brain (W.Wisden and MorrisB. J., eds), pp. 934. Academic Press, London.
  • Yamada K., Shibasaki T., Ysumori C., Imaki T., Hotta M., Wakabayashi I. and Demura H. (1996) Neuropeptide Y reverses corticotropin-releasing hormone- and psychological stress-caused shortening ofsodium pentobarbital-induced sleep in rats. Brain Res. 725, 272275.